In the BioHarmony Drug Report Database
Abaloparatide
Tymlos (abaloparatide) is a protein pharmaceutical. Abaloparatide was first approved as Tymlos on 2017-04-28. It is used to treat postmenopausal osteoporosis in the USA. The pharmaceutical is active against parathyroid hormone/parathyroid hormone-related peptide receptor. Tymlos’s patents are valid until 2038-04-30 (FDA).
Trade Name
|
Tymlos |
|---|---|
Common Name
|
abaloparatide |
ChEMBL ID
|
CHEMBL3301581 |
Indication
|
postmenopausal osteoporosis |
Drug Class
|
Peptides: parathyroid hormone related peptide |
Image (chem structure or protein)